JD HEALTH
06618
NTES-S
09999
BABA-W
09988
4
ALI HEALTH
00241
5
MEITUAN-W
03690
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | |
---|---|---|---|---|---|
Turnover | 53.25%336.47M | 90.94%510.26M | --219.56M | 90.17%267.23M | --140.52M |
Operating income | 53.25%336.47M | 90.94%510.26M | 219.56M | 90.17%267.23M | 140.52M |
Cost of sales | -63.61%-193.68M | -60.64%-268.52M | ---118.38M | -79.71%-167.15M | ---93.01M |
Operating expenses | -63.61%-193.68M | -60.64%-268.52M | -118.38M | -79.71%-167.15M | -93.01M |
Gross profit | 41.12%142.78M | 141.54%241.74M | 101.18M | 110.66%100.08M | 47.51M |
Selling expenses | -68.96%-20.55M | -71.39%-27.74M | ---12.16M | -23.08%-16.19M | ---13.15M |
Administrative expenses | -35.76%-23.5M | -90.05%-47.34M | ---17.31M | -36.28%-24.91M | ---18.28M |
Research and development expenses | -82.32%-10.15M | -93.29%-18.93M | ---5.57M | -50.06%-9.79M | ---6.53M |
Impairment and provision | 41.65%-304K | -139.77%-1.7M | ---521K | 23.27%-709K | ---924K |
-Other impairment is provision | 41.65%-304K | -139.77%-1.7M | ---521K | 23.27%-709K | ---924K |
Special items of operating profit | 227.66%7.98M | 34.38%-2.96M | ---6.25M | -172.09%-4.52M | --6.27M |
Operating profit | 62.13%96.26M | 225.38%143.06M | 59.37M | 195.17%43.97M | 14.9M |
Financing cost | -272.27%-443K | -217.05%-558K | ---119K | -33.33%-176K | ---132K |
Share of profits of associates | ---- | -91.97%-1.72M | ---767K | ---897K | ---- |
Earning before tax | 63.83%95.82M | 228.21%140.78M | 58.49M | 190.54%42.9M | 14.76M |
Tax | -56.80%-13.74M | -230.99%-20.25M | ---8.76M | -206.67%-6.12M | ---2M |
After-tax profit from continuing operations | 65.06%82.08M | 227.74%120.53M | 49.73M | 188.02%36.78M | 12.77M |
Earning after tax | 65.06%82.08M | 227.74%120.53M | 49.73M | 188.02%36.78M | 12.77M |
Minority profit | -364.10%-412K | -152.38%-22K | --156K | 180.00%42K | --15K |
Profit attributable to shareholders | 66.41%82.49M | 228.18%120.56M | 49.57M | 188.03%36.74M | 12.75M |
Basic earnings per share | 66.67%2.75 | 229.51%4.02 | 1.65 | 183.72%1.22 | 0.43 |
Diluted earnings per share | |||||
Currency Unit | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion |
Auditor | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.